

Les CNV du chromosome X


Damien Sanlaville

Service de Génétique, CHU de Lyon

Equipe GENDEV, CRNL, INSERM,
CNRS, UCBL1

Introduction

- Chromosome X
 - 156 Mb
 - 1805 gènes connus
- 2 chromosomes X chez une fille,
- 1 chez les garçons
- Plus de 100 gènes impliqués dans la DILX
- Chez les femmes, un des deux chromosomes X est inactivé de façon aléatoire mais certaines régions échappent à l'inactivation




1) Difficultés **d'analyse** des profils ACPA

Principes et exemples


Principe de l'ACPA

Pas de culture, pas de chromosome



Principe de l'ACPA

Pas de culture, pas de chromosome




Principe de l'ACPA

Sur le chromosome X : calcul différent


Garçon contre Garçon

ADN
témoin



+

ADN
patient




Hybridation
Sur des oligonucléotides

0 copie /
1 copie



2 copies /
1 copie



Log2 -infini

Log2 +1

Variations du nombre de copie
CNV


Principe de l'ACPA

Sur le chromosome X : calcul différent


Garçon contre Fille

ADN
témoin

ADN
patient




+



Hybridation
Sur des oligonucléotides

0 copie /
2 copies

Log2 -infini



2 copies /
2 copies

Log2 0

Variations du nombre de copie
CNV


Principe de l'ACPA

Sur le chromosome X : calcul différent


File contre Garçon

ADN
témoin

ADN
patient




+



Hybridation
Sur des oligonucléotides

1 copie /
1 copie

Log2 0



3 copies /
1 copie



Log2 +1

Variations du nombre de copie
CNV


Deletion (sex match)

Femme (-1)


Homme (-infini)



Red profile: Patient in Cy5 – Control 1 in Cy3
Green profile: Control 2 in Cy5 – Patient in Cy3



Combien de CNV ?




Red curve : Patient in A15 – Control 1 in A13
 Green curve: Control 2 in A15 – Patient in A13

Piège 1

- Femme avec caryotype XY (mutation *RA* mutation, *duplication NROB1 (DAX1)*)
 - Une duplication aura un log₂ ratio à 0
- Homme avec un caryotype XX (translocation impliquant SRY)

Piège2

- Dans les bases de données le sexe des patients est rarement renseigné



Reference	Shaikh_et_al_2009
Pubmed ID	19592680
Accession Number(s)	nsv520230
Sample Size	2026
Observed Gain	0
Frequency	Observed Loss 1
Observed Complex	0
Frequency	n/a

Homme/ Femme ?

Message

Une bonne analyse des profils

Permet

**De faire une bonne interprétation
clinique**


2) **Interpretation** des CNVs

- L'interprétation dépend de
 - Perte ou gain
 - Taille
 - Contenu en gène OMIM
 - Corrélation entre la clinique et les autres cas publiés
 - Hérité : *de novo* ou hérité
 - ...


Transmission

- En cas de VOUS : étude des parents
- Les CNVs hérités d'un parent sain sont généralement considérés comme bénins
- Mais pour le chromosome X...
- Généralement les CNVs sur le chromosomes X chez un garçon sont hérités de la mère

Importance de l'arbre généalogique




CNV hérité de la mère



Cas favorable
Probablement bénin


596,6 kb Xq13.1 duplication

- 2008
- Garçon
- RCIU
- Microcéphalie
- Cardiopathie
- Malformations rénale et cérébrale
- Déficience intellectuelle
- aCGH : VOUS
- Dup jamais décrite



Dye swap experiment

Famille non informative



Les parents demandent un DPN ...

3) Utilité de l'étude de l'inactivation du chromosome X

- Les femmes ont deux chromosomes X
- Un des deux chromosomes X est inactivé de façon aléatoire
- **2 points importants**
 - **Un défaut d'inactivation conduit à une disomie fonctionnelle du chromosome X**
 - L'inactivation biaisé d'un chromosome X peut être vu chez une femme sans phénotype

Disomie fonctionnelle (DF)

- Disomie fonctionnelle : expression en double dose de gènes exprimés normalement en simple dose
- Chez les hommes :
 - Duplication : DF
 - Grande DF : FCS
- Chez les femmes des remaniements de structure peuvent entrainer un phénotype ($t(X;A)$).

DF Xp

Functional Disomy of Proximal Xp Causes a Distinct Phenotype Comprising Early Hypotonia, Hypertelorism, Small Hands and Feet, Ear Abnormalities, Myopia and Cognitive Impairment

Matthew Hunter,^{1,2} Damien Bruno,^{1,2} and David J. Amor^{1,2,3*}

AJMG 2009

- Signes clés
 - Hypotonie
 - Retard de développement sévère
 - DI
 - Dysmorphie faciale
 - Epilepsie

DF Xq

Review

Open Access

Distal Xq duplication and functional Xq disomy

Damien Sanlaville^{*†1,2}, Caroline Schluth-Bolard^{†1,2} and Catherine Turleau^{†3}




Figure 1

Schematic representation of a Xq duplication transmission. Active X and Y chromosomes are in grey, inactive X is striped in black. A yellow star represents XIC. a) normal XY chromosomes; b) Xq duplication in male leading to Xq functional disomy, associated with an abnormal phenotype; c) Xq duplication in female with inactivation pattern skewed towards the duplicated X, associated with a normal phenotype; d) Xq duplication in female with inactivation pattern skewed towards the normal X leading to Xq functional disomy, associated with an abnormal phenotype.

Table 1: Comparison of clinical symptoms observed in three groups of patients with Xq duplications.

	Xq21q24 DF*	Xq26.3qter DF**	MECP2 duplication ***
Number of cases	12	21	47
Caesarean section	0/1	8/14	nr
Growth			
Growth retardation	9/10	17/19	2/3
Microcephaly	4/5	19/19	5/39
Facial dysmorphism			
Prominent metopic suture	nr	5/15	nr
Epicanthus fold	nr	5/6	1/8
Large ears	nr	9/12	4/20
Small mouth	nr	11/13	6/20
Abnormal palate/maxillar alveolus	nr	13/14	nr
Facial hypotonia	nr	3/4	19/28
Neurologic outcome			
Hypotonia		19/19	29/32
Developmental delay		19/19	47/47
Absent or delayed speech		11/14	46/47
Never walked or limited walking		12/14	21/34
Spacticity		3/4	17/21
Seizures		6/16	22/42
Malformations			
Hypoplastic genitalia/cryptorchidism	11/11	15/19	5/10
Others			
Severe feeding problems		10/14	15/29
Gastroesophageal reflux		4/7	13/17
Constipation		5/5	nr
Small feet		8/8	nr
Digital abnormalities		13/19	6/20
Recurrent infections		15/17	33/40



nr : not recorder

* modified from Cheng SF et al.[1] and Gabbett et al.[19]

** modified from Sanlaville et al.[5] and Smyk et al.[20]

*** modified from Ariani et al.[27], Meins et al.[28], Van Esch et al[26], Freiz et al.[29], del Gaudio et al.[30], Madrigal et al.[31], and Smyk et al.[20].

3) Utilité de l'étude de l'inactivation du chromosome X

- Les femmes ont deux chromosomes X
- Un des deux chromosomes X est inactivé de façon aléatoire
- **2 points importants**
 - Un défaut d'inactivation conduit à une disomie fonctionnelle du chromosome X
 - **L'inactivation biaisé d'un chromosome X peut être vu chez une femme sans phénotype**


Femmes et biais d'inactivation

Skewed X-Chromosome Inactivation Is a Common Feature of X-Linked Mental Retardation Disorders

AJHG 2002

Robert M. Plenge,^{1,*} Roger A. Stevenson,² Herbert A. Lubs,³ Charles E. Schwartz,² and Huntington F. Willard¹

b



Skewed X-Inactivation Patterns in XLMR Carriers

X-INACTIVATION PATTERN	FREQUENCY OF SKEWED X INACTIVATION ^a (%)		
	Female Control Subjects	XLMR Noncarriers ^b	XLMR Carriers ^c
≥90:10	3	2	30
≥80:20	9	15	48
≥70:30	30	41	63

X Chromosome–Inactivation Patterns of 1,005 Phenotypically Unaffected Females

AJHG 2006

James M. Amos-Landgraf,* Amy Cottle, Robert M. Plenge,† Mike Friez, Charles E. Schwartz, John Longshore, and Huntington F. Willard




Figure 1. The X-inactivation patterns of 1,005 females were assigned to 21 “bins” with a range of <math><2:98</math> to $>98:2$, with increments of 5%. These are normally distributed, with the mean of the distribution residing at 49:51 and the median at 50:50 (SD of the mean = 17).




Figure 2. Distributions of X-inactivation ratios of both newborn samples ($n = 590$) and unaffected adult females ($n = 415$).

Copy Number Changes on the X Chromosome in Women with and without Highly Skewed X-Chromosome Inactivation

CGR 2012

V. Jobanputra^a B. Levy^a A. Kinney^b S. Brown^c M. Shirazi^a C. Yu^d
J. Kline^{b, e, f} D. Warburton^d

Table 2. Copy number changes^a for women with and without highly skewed ($\geq 85\%$) X-chromosome inactivation

N= 90	Skewing $\geq 85\%$	Skewing 50 to $<75\%$
Number of women	45	45
Deletions	2	2
Deletions with genes	1	0
Women with deletions	2	1
Women with deletions with genes	1	0
Duplications	2	3
Duplications with genes	2	0
Women with duplications	2	3
Women with duplications with genes	2	0
Total CNCs	4	5
Total CNCs with genes	3	0
Women with one or more CNCs	3	4
Women with one or more CNCs with genes	2	0

Conclusion: HSXI in a blood sample is rarely due to X-chromosome copy number changes detectable by microarray.

« Grand » CNV > 5-10 Mb

Biais d'inactivation X inactivation


« petit » CNV < 5 Mb ?

biaisé ou non

^a Defined as changes ≥ 100 kb with ≤ 6 kb mean distance between markers and $\leq 50\%$ overlap with normal copy number variants according to <http://projects.tcag.ca/variation>.


Un exemple

- Deux frères nés en 1990 et 1994
 - Grossesse normal
 - Nés à terme
 - Développement normal jusqu'à 6 mois
 - A 6 mois : microcéphalie (-2,5 SD)
 - Retard de développement majeur
 - Marche à 2 ans
 - spasticité
 - Absence de langage,
 - Epilepsie



Conseil génétique

Résultat ACPA




Dye swap


Délétion de 40 kb sur le chromosome X comprenant en partie le gène of *SLC9A6*

Délétion de 40.57 kb : 135,080,988 to 135,121,564 pb (hg19)

aCGH result




Diagnosis de Christianson syndrome



Etude de l'inactivation du chromosome X

- Inactivation aléatoire chez la mère et pourtant elle est
 - En BS
 - conductrice


Inactivation aléatoire






- Heureusement la fille n'est pas conductrice

Autre situation en prénatal

- 3^o trimestre : macrosomie, dilatation biventriculaire, hypoplasie cérébelleuse
- Caryotype fœtal : 46,XX
- Décision IMG à 35 SA Parents
- Autopsie fœtale :
 - Hyperplasie thymique
 - Hypoplasie du vermis
 - Diminution des cellules de Purkinje
 - Hétérotopie



ACPA : 237 kb délétion on Xq12,
comprenant le gène *OPHN1*



Délétion de novo,

Etude Microsatellite : délétion sur le chromosome X d'origine paternelle

Biais d'inactivation complet

Délétion sur le chromosome X paternel, mais inactivation du chromosome X maternel

Biais d'inactivation défavorable chez une fille

Rocas et al, EJMG 2013

Message

Biais d'inactivation chez une mère

N'est pas obligatoirement associé au caractère pathogène d'un CNV mais l'inverse est vrai !

4) Régions PAR

- Des régions du chromosome X échappent au phénomène d'inactivation
 - PAR 1 (Xp): 2.5 Mb, comprend plusieurs gènes dont le gène *SHOX*
 - PAR2 (Xq): 400 kb (*IL9R*)
 - Environ 100 gènes le long du chromosome X

ORIGINAL PAPER

Copy number variation-based polymorphism in a new pseudoautosomal region 3 (PAR3) of a human X-chromosome-transposed region (XTR) in the Y chromosome


Avinash M. Veerappa · Prakash Padakannaya ·
Nallur B. Ramachandra

Table 2 Shared features of pseudoautosomal regions 1 and 2 with XTR (PAR3)

Shared features	PAR1	PAR2	XTR (PAR3)
Sequence homology	>98 %	>98 %	>98 %
Size	2.6 Mb	320 kb	~2.5 Mb
Has allelic homologues on both X and Y	Yes	Yes	Yes
Formed due to duplication	No	Yes	Yes
Gene escape inactivation	Yes	Yes	Yes
Recombination	Yes	Yes	Yes
Recombination frequency	Obligatory per meiosis	1 in 40 times	1 in 40 times
Genes	24	5	3

Il n'est pas clair si les CNV de PAR3 sont pathogènes

Fig. 1 Proposed PAR3 blocks on both the X and Y chromosomes indicating the size, genes, location, and the pseudoautosomal boundaries together with the already identified PAR1 and PAR2 features. Schematic representation of Yp11.2 blocks of three female subjects recombined with Xq21.3 regions of the X chromosome as revealed by whole-genome scan is also presented



5) CNV récurrents sur le chromosome X


Interprétation médicale dépend

Du sexe


De la localisation : PAR ou non PAR

CNVs récurrents...

- Description de quelques CNVs récurrents sur le chromosome X : NAHR mais pas toujours
- Identification de nombreux CNVs, essentiellement des gains (duplications) chez les garçons, non récurrents



Segmental Duplications Associated with XLID



Xp22.31 Wagenstaller et al. (Am J Hum Genet 81:738, 2007)
VCX3A, HDHD1A, STS, VCX, PNPLA4, and VCX2


Xp11.22 Giorda et al. (Am J Hum Genet 85:394–400,2009)
PORCN, PQPB1,BMP15,SHROOM4

Xp11.22. Froyen et al. (Am J Hum Genet 82:432, 2008)
RIBC1, HSD17B10 and HUWE1.

Xq21q22. (Mimault et al.: Am J Hum Genet 65:360, 1999)
PLP1

Xq28. Van Esch et al. (Am J Hum Genet 77:442, 2005)
MECP2

**Segmental Duplications
 Associated with XLID**



22.3	■ Wagenstaller et al.	Xp22.31 Wagenstaller (Am J Hum Genet 81:738, 2007) <i>VCX3A, HDHD1A, STS, VCX, PNPLA4, and VCX2</i>
22.2		
22.1	■ Gijbbers et al.	Xp22.2-p21.3. Honda et al. J Hum Genet 55:590, 2010
21.3	■ Whibley et al.	<i>REPS2, NHS, and ILRAPL1</i>
21.2		
21.1		Xp22.11p22.13 Gijbbers Clin Genet 2010
11.4		<i>AP1S2, CDKL5, SCML1, PDAA1, RPS6KAS, SMX, and ARX</i>
11.3	■ Froyen et al.	Xp11.22 Giorda et al. (Am J Hum Genet 85:394–400,2009)
11.23		<i>PORCN, PQPB1,BMP15,SHROOM4</i>
11.22	■ Froyen et al.	Xp11.22. Froyen et al. (Am J Hum Genet 82:432, 2008)
11.21		<i>RIBC1, HSD17B10 and HUWE1.</i>
11.1		Xq12-q13.1. (Bedeschi et al. Am J Med Genet 146A:1718, 2008)
11	■ Bedeschi et al.	<i>OPHN1</i>
12		Xq13.2q21.1. Koolen et al. (Hum Mutat 30:283, 2009).
13	■ Koolen et al.	<i>MED12, NLGN3, SLC16A2, KIAA2022, ATRX, and BRWD3</i>
21.1		
21.2		
21.3		
22.1	■ Mimault et al.,	Xq21q22. (Mimault et al.: Am J Hum Genet 65:360, 1999)
22.2		<i>PLP1</i>
22.3		
23		
24	■ Koolen et al.	Xq27.2-q27.3. Solomon et al.: J Med Genet 41:669, 2004
25	■ Koolen et al.	<i>SOX3</i>
26		Xq27.3q28 (Rio et al., Eur J Hum Genet 18:285, 2010).
27	■ Solomon et al.,	<i>FMR1, AFF2, IDS, MTM.</i>
	■ Rio et al.	
28	■ Van Esch et al.,	Xq28. Van Esch et al. (Am J Hum Genet 77:442, 2005)
		<i>MECP2</i>

**Segmental Duplications
Associated with XLID**

Microduplications Xp22.31

*VCX3A, HDHD1A, STS, VCX, PNPLA4,
et VCX2*

Interpretation of clinical relevance of X-chromosome copy number variations identified in a large cohort of individuals with cognitive disorders and/or congenital anomalies

EJMG 2012

Marjolein H. Willemsen*, Nicole de Leeuw, Arjan P.M. de Brouwer, Rolph Pfundt, Jayne Y. Hehir-Kwa, Helger G. Yntema, Willy M. Nillesen, Bert B.A. de Vries, Hans van Bokhoven, Tjitske Kleefstra

- 4407 patients
- 57 CNV sur le chromosome X non vus sur le caryotype (1,3 %)
- Taille de 10 kb à 8,5 Mb

-	Pathogène	VOUS	Polymorphe	Total
Duplication garçon	6	12	5	23
Duplication fille	1	0	11	12
Délétion garçon	7	5	0	12
Délétion fille	1	1	8	10
	15	18	24	57

- 0,3 % CNV pathogènes localisés sur le chromosome X
- 10 % *de novo*. Si hérité : 94 % de la mère
- Biais inactivation chez 21 des 34 mères conductrices : 4/21 (19 %) avec un biais

16 CNVs de la région Xp22.31 (*STS/VCXA3*) / 57 (28 %)

5 pertes de *STS/VCXA3* chez des garçons : VOUS

M	X-linked ichthyosis, concentration and emotional problems	Loss	Xp22.31	6.51–7.66	1.15 Mb/2 genes	NT	NT	<i>STS</i> <i>VCXA3</i>	(OMIM id 308100) X-linked ichthyosis (OMIM id 308100). The CNV explains part of the phenotype, but an association with the psychological problems is uncertain	[32,64–66] Also many cases reported in Decipher. Reported associations with ID are conflicting
---	---	------	---------	-----------	-----------------	----	----	----------------------------	---	--

Ichtyose plus troubles de l'attention, DI, épilepsie, autisme, spasticité, malformations

4 gains de *STS/VCXA3* chez des filles : Polymorphe

F	ID, Costeff syndrome (genetically confirmed)	Gain	Xp22.31	6.5–8.1	1.55 Mb/6 genes	NT	NT	1) <i>STS</i> 2) <i>VCXA3</i>	1) X-linked ichthyosis (OMIM id 308100).	[32,64–66] Also many cases reported in Decipher. Reported associations with ID are conflicting 2) Deletion of <i>VCXA3</i> was thought to be related to ID because of the gene's absence in XIJ patients with ID and its presence in XIJ patients without ID [64]. [32,64–66]
---	--	------	---------	---------	-----------------	----	----	----------------------------------	--	---

Retard de langage, ataxie cérébelleuse, hypotonie, retard de développement

7 pertes de *STS/VCXA3* chez des filles : Polymorphe

F	ID, epilepsy, alopecia, hearing loss	Loss	Xp22.31	6.5–8.1	1.55 Mb/6 genes	Mat	In patient: UI	<i>STS</i> , <i>VCXA3</i>	See above	See above
---	--------------------------------------	------	---------	---------	-----------------	-----	----------------	---------------------------	-----------	-----------

Epilepsie, ataxie cérébelleuse, DI, scoliose et anomalie des cheveux, malformations

6 CNVS comprenant *NLGN4 X*

Aucun cas de duplication de *MECP2*



Remaniements Xp22.31

- Patients (H/F) avec MCA/DI : 0,37 %
duplication Xp22.31 / 0,15 % dans une
population contrôle (Liu et *al.*, 2010). Idem Li
et al., 2010

Copy number gain at Xp22.31 includes complex duplication rearrangements and recurrent triplications

HMG 2011

Pengfei Liu¹, Ayelet Erez¹, Sandesh C. Sreenath Nagamani¹, Weimin Bi¹,



Etude de 61 cas

Table 3. Summary of clinical phenotypes for the subjects with the recurrent Xp22.31 duplication or triplication and the comparison with the summarized data from the literature

	Recurrent duplications (<i>n</i> = 12)		Recurrent Triplications (<i>n</i> = 3)		All duplications from the literature (<i>n</i> = 35) ²⁰
	Male (<i>n</i> = 11)	Female (<i>n</i> = 3)	Male (<i>n</i> = 2)	Female (<i>n</i> = 1)	
Gastro-esophageal reflux	3 (27%)	–	1 (50%)	–	3 (9%)
Delay					
Gross motor	6 (55%)	2 (67%)	2 (100%)	1	24 (69%)
Speech	7 (64%)	2 (67%)	2 (100%)	1	
Developmental regression	1 (9%)	1 (33%)	–	–	–
Seizures	1 (9%)	1 (33%)	–	–	4 (11%)
Hypotonia	3 (27%)	1 (33%)	1 (50%)	1	7 (20%)
Behavior problems					
Autism spectrum	7 (64%)	–	–	–	13 (37%)
ADHD	–	–	2 (100%)	–	–
Macrocephaly >95%	4 (36%)	–	–	1	–
Microcephaly <5%	–	1 (33%)	–	–	4 (11%)
Short stature	1 (9%)	1 (33%)	1 (50%)	–	2 (6%)
MRI/CT brain abnormalities	2 (18%)	1 (33%)	–	–	–
EEG abnormalities	2 (18%)	1 (33%)	–	–	–

‘–’ indicates the feature is not present in the corresponding category or this information is not available. In the subjects with duplications, there are two siblings and one set of twins. Note that the data from the last column are phenotypes collected from different types of Xp22.31 gains (not restricted to recurrent duplications).


With these considerations, it remains uncertain whether the recurrent Xp22.31 duplications alone are associated with abnormal phenotypes. Further clinical study is warranted for more individuals with the Xp22.31 recurrent or simple nonrecurrent duplications, triplications and other complex rearrangements in order to reach conclusions whether these changes are pathogenic or benign CNVs.

Facteur de risque

Et les délétions

Remaniements Xp22.31

- Lesca *et al.*, 2005; Mochel *et al.*, 2008; Cueves-Covarrubias *et al.*, 2008 : délétion *VCX3A* : n'explique pas la DI.




Avis de l'ISCA sur CNV (*STS*)

<http://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/index.shtml>

- Perte de fonction :
 - Ichtyose chez les garçons
 - Femme atteinte : homozygote ?
 - Possible Clinical Interpretation(s): **Pathogenic** (males); Pathogenic/carrier status (females)
- Gain de fonction :
 - Peu de données en faveur de la pathogénéicité
 - Possible Clinical Interpretation(s): **Benign** (males and females)
- Furrow et al. 2011 : 72 garçons dup *STS/VCX* : Polymorphisme

Duplication of the STS Region in Males Is a Benign Copy-Number Variant

Aubry Furrow,¹ Aaron Theisen,¹ Lea Velsher,² Erawati V. Bawle,³ Sujatha Sastry,³ Nancy J. Mendelsohn,⁴ Kristi Jarvis,⁴ Lisa G. Shaffer,^{1*} and David Chitayat^{5,6}



72 males studied

Based on our results and previously published data, duplication of the STS region in males is likely a benign finding and does not appear to contribute to the abnormal phenotypes found in our patient population submitted for diagnostic microarray analysis. Nevertheless, contributions to a digenic two-hit model or reduced-penetrance dosage effects of other genes in the genomic region encompassed by the CNV gain cannot be ruled out by the present data.

Duplication / Triplication Xq21q22

PLP1

Syndrome de Pelizaeus-Merzbacher

Syndrome de Pelizaeus- Merzbacher

- Forme infantile précoce de leucodystrophie cérébrale progressive
- Démyélinisation de la substance blanche cérébrale
- Clinique
 - Tremblement de la tête
 - Nystagmus
 - Paraplégie spasmodique
 - Déficience intellectuelle
 - Mouvements athétosiques

Three or more copies of the proteolipid protein gene *PLP1* cause severe Pelizaeus–Merzbacher disease

Brain 2005

Nicole I. Wolf,^{1,6} Erik A. Sistermans,⁷ Maria Cundall,¹ Grace M. Hobson,^{8,9}

Table 1 *Clinical characteristics of patients 1–5*

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Age at first symptom	Birth (nystagmus; stridor)	First weeks of life (nystagmus)	3 weeks (nystagmus)	Birth (nystagmus)	Birth (nystagmus; hypotonia)
Age at death	9 months	7 months	Alive (4.7 years)	Alive (14 months)	Alive (15 months)
Nystagmus	+	+	+	+	+
Seizures	++	++	–	+	++
Stridor	+	+	–	+	–
Head control	None	None	Poor	None	None
Muscular hypotonia	+	+	+	+	+
Spasticity	–	–	Mild	Mild	–
Nerve conduction studies	Normal	Not performed	Normal	Not performed	Unreliable

5 copies *PLP1*

4 copies *PLP1*

3 copies *PLP1*


PLP1 (Proteolipid Protein) sensible au dosage génique

6) Difficultés d'interprétation de certains CNV sur le chromosome X et de conseil

- Effet de position ?

Exploring the Potential Role of Disease-Causing Mutation in a Gene Desert: Duplication of Noncoding Elements 5' of *GRIA3* is Associated with *GRIA3* Silencing and X-Linked Intellectual Disability

Céline Bonnet,¹ Alice Masurel-Paulet,² Asma Ali Khan,¹ Mylène Béri-Dexheimer,¹ Patrick Callier,³ Francine Mugneret,³ Christophe Philippe,¹ Christel Thauvin-Robinet,² Laurence Faivre,² and Philippe Jonveaux^{1*}



Homme
Epilepsie
DI sévère
Dysmorphie faciale
Hypotonie axiale
Cyphose

Dup 970 kb Xq
Pas de gène

GRIA3 encodes glutamate receptor ionotropic AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)




Figure 2. Reverse transcriptase quantitative real-time PCR analysis using three primer sets (exons 3–4, exons 7–8, exons 12–13) shows loss of *GRIA3* expression for the patient relative to a male control.


Absence d'ARNm de *GRIA3*
 CNV implique un facteur de transcription ?

6) Difficultés d'interprétation de certains CNV sur le chromosome X et de conseil

- Effet de position ?
- Attention aux « Dogmes »

Sporadic Infantile Epileptic Encephalopathy Caused by Mutations in *PCDH19* Resembles Dravet Syndrome but Mainly Affects Females


Christel Depienne^{1,2,3*}, Delphine Bouteiller², Boris Keren¹, Emmanuel Cheuret⁴, Karine Poirier⁵, Oriane Trouillard¹, Baya Benyahia¹, Chloé Quelin⁵, Wassila Carpentier⁶, Sophie Julia⁴, Alexandra Afenjar^{1,7}, Agnès Gautier⁸, François Rivier⁹, Sophie Meyer¹⁰, Patrick Berquin¹¹, Marie Hélias¹², Isabelle Py¹³, Serge Rivera¹⁴, Nadia Bahi-Buisson¹⁵, Isabelle Gourfinkel-An^{2,15,16}, Cécile Cazeneuve¹, Merle Ruberg^{2,3}, Alexis Brice^{1,2,3}, Rima Nabbout^{16,17}, Eric LeGuern^{1,2,3}



*Délétion PCHD19
de novo*

A Normal individual
(male or female)


PCDH19-positive cells
only



Asymptomatic

B Mutated males


PCDH19-negative cells
only



Asymptomatic

C Mutated females
and mosaic mutated males


PCDH19-negative and PCDH19-
positive cells coexist



Epilepsy and
mental retardation

Mutation
hémizygote chez
les garçons :
asymptomatique

Mutation
hétérozygote
chez une femme
: DI et épilepsie



Mutation
hémizygote chez
les garçons :
asymptomatique

Mutation
hétérozygote
chez une femme
: DI et épilepsie


Figure 6. Schematic illustration of the cellular interference mechanism associated with *PCDH19* mutations. A) In normal individuals,

Mécanisme d'interférence cellulaire

Cas d'un garçon symptomatique

Pourquoi ?

Cas d'un garçon symptomatique



Garçon symptomatique :
étude des fibroblastes :
mosaïque !

7) CNV du chromosome CNV et découverte non sollicité

Exemple de *DMD*

Découverte non sollicitée

- Patiente adressée pour
 - Encéphalopathie épileptique
 - Nystagmus,
 - Microcéphalie progressive
 - Hypoplasie cérébelleuse à l'IRM
 - *Décès à 14 mois*
 - ACPA : délétion de 227.5 kb sur le chromosome X emportant les exons 3 à 9 du gène *DMD*, prédictif de **BMD**.
- Etude parentale :
 - Le père est porteur asymptomatique mais a des CPK modérément élevées à 1016 IU/l.

8) Puce à façon du chromosome X

Clinical Utility of the X-Chromosome Array

AJMG 2012

Yuri A. Zarate,* Alka Dwivedi, Frank O. Bartel, M. Allison Bellomo, Sara S. Cathey, Neena L. Champaigne, L. Kate Clarkson, Barbara R. DuPont, David B. Everman, Joseph S. Geer, Barbara C. Gordon, Angie W. Lichty, Michael J. Lyons, R. Curtis Rogers, Robert A. Saul, Richard J. Schroer, Steven A. Skinner, and Roger E. Stevenson

TABLE III. Results of Previous Studies That Used Various X-Chromosome Array Platforms

References	Array platform	Indication	Frequency of pathogenic or likely pathogenic CNVs (%)	Comments
Froyen et al. [2007]	1,875 BAC/PAC clones	ID	5/108 (4.6)	3 dup, 2 del
Honda et al. [2010]	1,001 BAC/PAC clones	ID	10/144 (6.9)	13 CNVs, 10 dup, 3 del
Kousoulidou et al. [2007]	558 X-specific 400–600 bp target sequences	XLID	1/20 (5)	1 known dup
Lugtenberg et al. [2006]	1,460 BAC clones	XLID	3/40 (7.5)	3 dup
Madrigal et al. [2007]	1,600 BAC clones	XLID and XL trait	8/54 (14.8)	5 dup, 3 del
Whibley et al. [2010]	385 K Nimblegen [®] oligonucleotide	XLID	25/251 (10)	18 dup, 7 del
This study	28, 44, and 105 k OGT [®] oligonucleotide	Multiple	16/59 (27)	16 del

BAC, bacterial artificial chromosome; CNVs, copy number variants; Del, deletion; Dup, duplication; ID, intellectual disability; OGT, Oxford Gene Technology; PAC, P1-derived artificial chromosome; XLID, X-linked intellectual disability.

Custom oligonucleotide array-based CGH: a reliable diagnostic tool for detection of exonic copy-number changes in multiple targeted genes

EJHG 2013

Aurélien Vasson¹, Céline Leroux¹, Lucie Orhant¹, Mathieu Boimard¹, Aurélien Toussaint¹, Chrystel Leroy¹, Virginie Commere¹, Tiffany Ghiotti¹, Nathalie Deburgrave¹, Yoann Saillour², Isabelle Atlan¹, Corinne Fouveaut¹, Cherif Beldjord^{1,2}, Sophie Valleix^{1,2}, France Leturcq^{1,2}, Catherine Dodé^{1,2}, Thierry Bienvenu^{1,2}, Jamel Chelly^{1,2} and Mireille Cossée^{*,1,2}


- 12 gènes / 26 sur le chromosome X
- CNV identifiés dans les gènes suivants :
 - *DMD* : 9 dup et 6 del de 2,2 kb à 772 kb
 - *CDKL5* : 2 del de 6,2 kb et 294 kb
 - *DCX* : 1 del et 2 dup : 7,9-740 kb
 - *KAL1* : 3 del : 91-2297 kb
 - *F8* : 1 del de 38,6 kb

UCSC Genome Browser on Human Feb. 2009 (GRCh37/hg19) Assembly

move <<< << < > >> >>> zoom in 1.5x 3x 10x base zoom out 1.5x 3x 10x 100x

chrX:47,442,093-47,442,720 628 bp. chrX:47,442,093-47,442,720

go [More on-site workshops available!](#)



Régions introniques: quelles conclusions?
100 petits CNV par array

Fine-Scale Survey of X Chromosome Copy Number Variants and Indels Underlying Intellectual Disability

AJHG 2010

Annabel C. Whibley,¹ Vincent Plagnol,^{1,2} Patrick S. Tarpey,³ Fatima Abidi,⁴ Tod Fullston,^{5,6}

Table 1. Summary of Rare X Chromosome CNVs

	All CNVs	<1 kb	1-10 kb	10-100 kb	100-500 kb	>500 kb
Deletions	498 (440)	182 (161)	224 (202)	86 (71)	4 (4)	2 (2)
Duplication	454 (421)	150 (146)	174 (165)	84 (69)	31 (26)	15 (15)
Total	952 (861)	332 (307)	398 (367)	170 (140)	35 (30)	17 (17)

Total call numbers are stated, with numbers in parentheses indicating the number of distinct CNV loci after merging calls across samples.

Conclusions

Comment interpréter les CNVs
localisés sur le chromosome X



ELSEVIER

Contents lists available at [SciVerse ScienceDirect](http://www.elsevier.com/locate/ejmg)

European Journal of Medical Genetics

journal homepage: <http://www.elsevier.com/locate/ejmg>



Original article

Sporadic male patients with intellectual disability: Contribution of X-chromosome copy number variants

M. Isrie^a, G. Froyen^b, K. Devriendt^a, T. de Ravel^a, J.P. Fryns^a, J.R. Vermeesch^a, H. Van Esch^{a,*}

^aCenter for Human Genetics, University Hospitals Leuven, KU Leuven, Herestraat 49, 3000 Leuven, Belgium

^bHuman Genome Laboratory, VIB, Center for Human Genetics, KU Leuven, Herestraat 49, 3000 Leuven, Belgium





Fig. 1. Proposed decision tree for classification of gene-containing sporadic X-CNVs in males.

CNV chromosome X



**Brainstorming
Cytogeneticist
Clinician**



Take home message

- Bien analyser le profil +++ (sexe patient ?)
- Interprétation clinique dépend du sexe du patient
- Une étude familiale est souvent nécessaire
- Un biais d'inactivation n'est pas synonyme de pathogène
- Combiner les différents éléments avant de conclure

Perspectives

NGS

ORIGINAL ARTICLE

X-exome sequencing of 405 unresolved families identifies seven novel intellectual disability genes

H Hu^{1,41}, SA Haas^{2,41}, J Chelly^{3,4}, H Van Esch⁵, M Raynaud^{6,7,8}, APM de Brouwer⁹, S Weinert^{10,11}, G Froyen^{12,13}, SGM Frints^{14,15}, F Laumonier^{6,7}, T Zemojtel², MI Love², H Richard², A-K Emde², M Bienek¹, C Jensen¹, M Hambrock¹, U Fischer¹, C Langnick¹⁰, M Feldkamp¹⁰, W Wissink-Lindhout⁹, N Lebrun^{3,4}, L Castelnau^{3,4}, J Rucci^{3,4}, R Montjean^{3,4}, O Dorseuil^{3,4}, P Billuart^{3,4}, T Stuhlmann^{10,11}, M Shaw^{16,17}, MA Corbett^{16,17}, A Gardner^{16,17}, S Willis-Owen^{16,18}, C Tan¹⁶, KL Friend¹⁹, S Belet^{12,13}, KEP van Roozendaal^{14,15}, M Jimenez-Pocquet⁸, M-P Moizard^{6,7,8}, N Ronce^{6,7,8}, R Sun², S O'Keefe², R Chenna², A van Bömmel², J Göke², A Hackett²⁰, M Field²⁰, L Christie²⁰, J Boyle²⁰, E Haan^{16,19}, J Nelson²¹, G Turner²⁰, G Baynam^{21,22,23,24}, G Gillissen-Kaesbach²⁵, U Müller^{26,27}, D Steinberger^{26,27}, B Budny²⁸, M Badura-Stronka²⁹, A Latos-Bieleńska²⁹, LB Ousager³⁰, P Wieacker³¹, G Rodríguez Criado³², M-L Bondeson³³, G Annerén³³, A Dufke³⁴, M Cohen³⁵, L Van Maldergem³⁶, C Vincent-Delorme³⁷, B Echenne³⁸, B Simon-Bouy³⁹, T Kleefstra⁹, M Willemsen⁹, J-P Fryns⁵, K Devriendt⁵, R Ullmann^{1,42}, M Vingron², K Wrogemann^{1,40}, TF Wienker¹, A Tzschach¹, H van Bokhoven⁹, J Gecz^{16,17}, TJ Jentsch^{10,11}, W Chen^{1,10}, H-H Ropers¹ and VM Kalscheuer¹

X-linked intellectual disability (XLID) is a clinically and genetically heterogeneous disorder. During the past two decades in excess of 100 X-chromosome ID genes have been identified. Yet, a large number of families mapping to the X-chromosome remained unresolved suggesting that more XLID genes or loci are yet to be identified. Here, we have investigated 405 unresolved families with XLID. We employed massively parallel sequencing of all X-chromosome exons in the index males. The majority of these males were previously tested negative for copy number variations and for mutations in a subset of known XLID genes by Sanger sequencing. In total, 745 X-chromosomal genes were screened. After stringent filtering, a total of 1297 non-recurrent exonic variants remained for prioritization. Co-segregation analysis of potential clinically relevant changes revealed that 80 families (20%) carried pathogenic variants in established XLID genes. In 19 families, we detected likely causative protein truncating and missense variants in 7 novel and validated XLID genes (*CLCN4*, *CNKSR2*, *FRMPD4*, *KLHL15*, *LAS1L*, *RLIM* and *USP27X*) and potentially deleterious variants in 2 novel candidate XLID genes (*CDK16* and *TAF1*). We show that the *CLCN4* and *CNKSR2* variants impair protein functions as indicated by electrophysiological studies and altered differentiation of cultured primary neurons from *Cln4*^{-/-} mice or after mRNA knock-down. The newly identified and candidate XLID proteins belong to pathways and networks with established roles in cognitive function and intellectual disability in particular. We suggest that systematic sequencing of all X-chromosomal genes in a cohort of patients with genetic evidence for X-chromosome locus involvement may resolve up to 58% of Fragile X-negative cases.


Table 2. Variants identified in novel XLID genes and candidates

Family ID	Gene	Variant	PS score	C score	Additional information (numbers indicate informative affected/unaffected males tested for segregation/obligate female carriers)	Summary of clinical information for families per gene
<i>Likely pathogenic variants in novel and validated XLID genes</i>						
MRX49 ⁵¹ /L19	CLCN4	p.Asp155Serfs*18	20	36	4/2/2, F, encodes a proton-chloride antiporter	Non-specific borderline to profound ID
MRX15 ⁶² /T8	CLCN4	p.Gly731Arg	8	29	F, cytosolic cystathionine-β-synthase domain, may impair transporter opening	
N70	CLCN4	p.Gly78Ser	14	25	1/0/1, F, transmembrane domain	
AU27	CLCN4	p.Leu221Val	8	25	2/0/4, F, transmembrane domain	
AU9	CLCN4	p.Val536Met	14	27	3/0/7, F, transmembrane domain	
P180	CNKSR2	p.Asp152Argfs*8	20	19	3/0/1, F, C, encodes connector enhancer of kinase suppressor of Ras 2, interacts with PSD95, XLID protein DLG3, ID/autism protein SHANK3	ID, attentional problems, hyperactivity, language loss, seizures ⁹⁹
P58	FRMPD4	p.Cys618Valfs*8	20	38	5/2/2, encodes FERM and PDZ domain containing 4, interacts with PSD95, with ARHGEF7, a guanine nucleotide exchange factor with a role in the regulation of spine morphogenesis, and with actin filaments ^{104,123}	Mild to severe ID with variable seizures, lack of speech or poor speech, behavioral problems
L87	FRMPD4	p.Cys553Arg	4	16	De novo	
D60	KLHL15	p.Tyr394Ilefs*61	20	33	8/1/4, encodes kelch-like 15, large family with 8 affected in three generations	Mild to moderate ID, mild facial features
MRX56 ⁶⁶ /AU10	LAS1L	p.Ala269Gly	10	18	5/0/19, C, encodes Las1-like, ribosome biogenesis	Wilson-Turner syndrome, ⁶⁶ mild to moderate ID, obesity, facial features, speech impairment, variable behavioral problems, gynecomastia, small/undescended testes/hypogonadism, tapering fingers
T50	LAS1L	p.Arg415Trp	11	14	3/2/3, C	
MRX61/T11	RLIM	p.Pro587Arg	11	13	3/1/3, encodes ring finger protein, LIM domain interacting, E3 ubiquitin-protein ligase, binds to transcription factors that play important roles for the development of neuronal structures and cell types	Non-specific mild to profound ID in two families with variable behavior problems, ID, microcephaly, micrognathia and cryptorchidism in all affected of one family
D72	RLIM	p.Arg387Cys	12	12	1/2/8	
AU31	RLIM	p.Arg599Cys	14	18	2/3/3	
D177	USP27X	p.Ser342Argfs*14	20	10	3/0/2, encodes ubiquitin-specific peptidase 27, interacts with USP22 which deubiquitinates core histones H2A and H2B, USP22 interacts with ARID gene KIF7	Borderline to moderate ID, variable absent or poor speech and behavioral problems
L75	USP27X	p.Tyr381His	12	11	1/1/2, this residue is part of a domain (IPR001394) and using HOPE web server (see URLs) the variant is predicted to cause an empty space in the core of the protein or protein complex and to cause loss of hydrophobic interactions	
<i>Potentially deleterious changes in novel candidate genes</i>						
L56	CDK16	p.Trp326Valfs*5	20	37	4/1/3, encodes cyclin-dependent kinase 16, also known as PCTK1, PCTAIRE1, and PCT-1	ID, spastic paraplegia
N67	TAF1	p.Asn493Asp	13	19	2/0/2, encodes TATA box binding protein (TBP)-associated factor, 250 kDa, subunit of TAFIID which plays a key role transcription initiation. Drosophila homolog phosphorylates histone H2B, variants in TAF2 cause ARID ^{78,79}	Mild to severe ID, facial features
D185	TAF1	p.Arg1190Cys	14	27	2/4/7	

Abbreviations: C, clinical evidence; F, functional evidence from this study; HGMD, Human Gene Mutation Database; ID, intellectual disability; PS, prioritization score, includes type of variant, evolutionary conservation and predictions from Polyphen2 and SIFT; C score obtained by using Combined Annotation-Dependent Depletion (CADD);³⁵ XLID, X-linked intellectual disability.

2 brothers with ID : Xp22.11 deletion of 33.88 kb (24,015,258-24,049,144,hg19)


2010



UCSC Genome Browser on Human Feb. 2009 (GRCh37/hg19) Assembly

move <<< << < > >> >>> zoom in 1.5x 3x 10x base zoom out 1.5x 3x 10x


position/search chrX:24,015,258-24,049,144 [gene](#) jump clear size 33,887 bp. configure



2 exons of *KLHL15*

Family study with qPCR

2010



→ VOUS

AJMG 2014

Intragenic Rearrangements in X-Linked Intellectual Deficiency: Results of a-CGH in a Series of 54 Patients and Identification of *TRPC5* and *KLHL15* As Potential XLID Genes

Cécile Mignon-Ravix,^{1,2} Pierre Cacciagli,^{1,2,3} Nancy Choucair,^{1,2,4} Cornel Popovici,³
Chantal Missirian,³ Mathieu Milh,^{1,2,5} André Mégarbané,^{1,2,4} Tiffany Busa,³ Sophie Julia,⁶
Nadine Girard,^{2,7} Catherine Badens,^{1,2,3} Sabine Sigaudy,³ Nicole Philip,^{1,2,3} and Laurent Villard^{1,2*}

+ *KHLK15* mutations

↓
Pathogenic

ACLF 2016

Cytogénétique

Christine Bel
Anne Fautrelle
Audrey Gaillard
Brigitte Jelassi
Sylvie Josué
Catherine Hempel
Chantal Lavert
Michelle Martin
Caroline Perbet
Christine Valex
Corinne Buis
Nicolas Chatron
Caroline Schluth-Bolard

ACPA

Marianne Till
Audrey Labalme
Eudeline Alix
Christelle Angei
Chantal Beche
Clément Bonnefille
Laurence Caine
Hélène Guilbert
Isabelle Morin
Jessica Michel

Cliniciens

Patrick Edery
Carine Abel
Dominique Boggio
Marie Pierre Cordier
Sophie Dupuis-Giraud
Gaetan Lesca
Audrey Putoux
Massimiliano Rossi
James Lespinasse

Réseau Achropuces



Inserm

Institut national
de la santé et de la recherche médicale